We got an excellent bounce in the market today, which was followed by a solid earnings report from Amazon. That should help support the market in the near term.
I picked up a position in RNN because the company announced they will be releasing some initial data at the ASCO conference, which has abstracts May 16th and the conference on June 2nd.
|
[Free Download] The $2.4 Million Trader Playbook 
If you don’t make enough from your trades or you’re unhappy with your income, this is something you’ll really want to check this out… |
Big news!
The Nucleus application process is back open after being close for a few months! I’ve opened the doors and put together some homework assignments to weed out those who aren’t serious.
This is your opportunity to bust through the front door if you are dedicated about profits, skill, and opportunity.
Follow me along here to get started.
Just a reminder, charts and targets are updated every Monday morning!
New Catalyst Swing names (1 – 4 week holds) I am watching…
Rexahn Pharmaceuticals (RNN)
Catalyst Dates: Phase 2 data due out May 16 and June 2
Buy Zone: $1.60 to $1.70
Profit Zone: $2.00 or higher
Stop Zone: $1.40 or below
Catalyst Swing names (1 – 4 week holds) I am watching…
Dermira (DERM)
Catalyst Dates: FDA Approval date of June 30th
Buy Zone: $8.00 to $8.50
Profit Zone: $9.50 or higher
Stop Zone: $7.80 or below
MEI Pharma (MEIP)
Catalyst Dates: Two Phase 1 and one Phase 2 data due in the second quarter (likely around early June)
Buy Zone: $1.90 to $2.10
Profit Zone: $2.80 or higher
Stop Zone: $1.80 or below
Catalyst Biosciences (CBIO)
Catalyst Dates: Phase 2 data in July
Buy Zone: $23.00 to $25.00
Profit Zone: $29.00 or higher
Stop Zone: $22.00 or below
Pain Therapeutics (PTIE)
Catalyst Dates: Phase 3 data due May 21
Buy Zone: $7.50 to $8.25
Profit Zone: $9.50 or higher
Stop Zone: $7.00 or below
Sophiris Bio (SPHS)
Catalyst Dates: Phase 2 prostate cancer data due out late 2Q
Buy Zone: $2.00 to $2.20
Profit Zone: $2.50 or higher
Stop Zone: $1.90 or below
Eleven Biotherapeutics (EBIO)
Catalyst Dates: Phase 3 data due May 21
Buy Zone: $1.50 to $1.65
Profit Zone: $2.05 or higher
Stop Zone: $1.40 or below
Insys Therapeutics (INSY)
Catalyst Dates: May 22 Advisory Committee Meeting
Buy Zone: $6.00 to $6.40
Profit Zone: $7.00 or higher
Stop Zone: $5.45 or below
Esperion Therapeutics (ESPR)
Catalyst Dates: Two Phase 3 data sets due out in May
Buy Zone: $70.00 to $72.00
Profit Zone: $77.00 or higher
Stop Zone: $69.00 or below
Corium International (CORI)
Catalyst Dates: Phase 1 data due likely in May
Buy Zone: $10.25 to $10.75
Profit Zone: $12.00 or higher
Stop Zone: $9.50 or below
AcelRx (ACRX)
Catalyst Dates: European approval likely due within next two months
Buy Zone: $2.00 to $2.20
Profit Zone: $2.50 or higher
Stop Zone: $1.80 or below
Kitov Pharma (KTOV)
Catalyst Dates: FDA Approval date of May 31
Buy Zone: $2.10 to $2.30
Profit Zone: $2.75 or higher
Stop Zone: $2.00 or below
TherapeuticsMD (TXMD)
Catalyst Dates: FDA approval date of May 29th
Buy Zone: $5.00 to $5.45
Profit Zone: $6.00 or higher
Stop Zone: $4.50 or below
Dova Pharmaceuticals (DOVA)
Catalyst Dates: FDA approval date of May 21
Buy Zone: $25.00 to $27.00
Profit Zone: $30.00 or higher
Stop Zone: $24.00 or below
Nabriva Therapeutics (NBRV)
Catalyst Dates: Phase 3 antibiotic data due out “spring 2018”
Buy Zone: $5.00 to $5.40
Profit Zone: $7.00 or higher
Stop Zone: $4.90 or below
